Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim vs rhTPO for platelet engraftment after haploidentical HSCT
ChiCTR2600121211Phase 4Not yet recruiting
- Sponsor
- Third Xiangya Hospital, Central South University
- Start
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes, Hormones & Growth Factors → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of romiplostim and thrombopoietin in hematopoietic malignancies, leukemia, lymphoma and 1 more (2 arms), sponsored by Third Xiangya Hospital, Central South University. Primary endpoint: Cumulative incidence of platelet engraftment on day 60 post-transplant. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
romiplostimthrombopoietin
03
Conditions
hematopoietic malignanciesleukemialymphomamyelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR2600121211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121211.